Italian Validation of the Childhood Atopic Dermatitis Impact Scale: A Contribution to Its Clinical Application  by Neri, Erica et al.
Italian Validation of the Childhood Atopic Dermatitis
Impact Scale: A Contribution to Its Clinical Application
Erica Neri1, Francesca Agostini1, Paola Gremigni1, Francesca Gobbi2, Giulia Casu1, Sarah L. Chamlin3
and Fiorella Monti1
To contribute to the application of the Childhood Atopic Dermatitis Impact Scale (CADIS), 135 Italian parents of
children with atopic dermatitis (AD) aged birth to 6 years completed: CADIS, Infants Dermatitis Quality of Life
Index (IDQOL) or Children’s Dermatology Life Quality Index (CDLQI), and Dermatitis Family Impact 10-item
questionnaire (DFI). A subsample of 66 caregivers completed the CADIS again, 48 hours later. Disease severity
was measured with the Severity Scoring of Atopic Dermatitis (SCORAD) index. Exploratory factor analyses
almost replicated the general factor structure of the original CADIS, established on a US sample. However, some
differences emerged, probably due to cultural differences. A reduced version of the original CADIS was also
obtained, based on the exploratory factor analyses, to facilitate use in clinical settings. The original and the
shorter versions were tested for reliability: overall Cronbach’s a and test–retest reliability for the child- and
parent-related scales were acceptable. Regarding concurrent validity, estimates showed the CADIS to correlate
adequately with SCORAD, IDQOL-CDLQI, and DFI. Multiple comparison tests for discriminant validity revealed
significant differences between extreme groups based on AD severity for all five domains of CADIS. The original
CADIS showed adequate validity and reliability in Italy as well, and the shorter version showed promising
psychometric properties.
Journal of Investigative Dermatology (2012) 132, 2534–2543; doi:10.1038/jid.2012.199; published online 14 June 2012
INTRODUCTION
Atopic dermatitis (AD) is the most common chronic
inflammatory skin disease in childhood, affecting 10–20%
of children in Europe (Hanifin, 2002) and 17% in the United
States (Laughter et al., 2000). Adverse consequences of this
disorder on children, like distress, irritability, behavioral
problems, and sleep dysfunctions, have been well-documen-
ted (Beattie and Lewis-Jones, 2006; Chamlin, 2006; Ricci
et al., 2007). It has also been shown that with worsening
disease severity, the negative impact on child’s quality of life
(QoL) increases (Ben-Gashir et al., 2004; Beattie and Lewis-
Jones, 2006; Zuberbier et al., 2006; Mozaffari et al., 2007).
The onset of the disease in the first years of life (Kay et al.,
1994) implies an impact on the emotional, economical,
physical, and social well-being of the whole family
(Balkrishnan et al., 2003; Mozaffari et al., 2007; Chamlin
and Chren, 2010). Taking care of a child with AD, in fact,
entails an extra work for parents, tied to the daily care and
treatment of the child (Elliott and Luker, 1997); many studies
have evidenced how the whole family is influenced in terms
of lower social support, higher stress tied to one’s own
parental role, and greater difficulties in managing discipline
(Daud et al., 1993; Ricci et al., 2007; Monti et al., 2011).
Different scales have been developed to measure QoL in
children with AD and their parents. A recent review on QoL
instruments in AD (Rehal and Armstrong, 2011) underlines
how, in the past 25 years, up to 14 instruments have been
created and used in clinical trials on patients with AD, but the
most frequently used have been: the Children’s Dermatology
Life Quality Index (CDLQI), DLQI, Infants Dermatitis Quality
of Life Index (IDQOL), and Dermatitis Family Impact 10-item
questionnaire (DFI). Specifically, the CDLQI (Lewis-Jones and
Finlay, 1995) and the Infants’ Dermatitis Quality of Life Index
(IDQOL; Lewis-Jones et al., 2001) are 10-item questionnaires
for measuring QoL in children with AD from 4 to 16 years
(with help from the parents for younger children) and in
infants from birth to 4 years (to be completed by the parents),
respectively. The DLQI (Finlay and Khan, 1994) is a 10-item
questionnaire as well, but evaluates QoL in the routine
clinical practice with adult patients, over 18 years of age.
The DFI (Lawson et al., 1998) measures how the child’s AD
affects family life.
Although all these instruments have shown good internal
consistency, validity, sensitivity to change, and ease of use,
they do not pay enough attention to the emotional effects of
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AD (Chamlin et al., 2005). As the emotional burden of a
chronic disease like AD has been found to be relevant in
children and their parents (Chamlin et al., 2004; Al Robaee
and Shahzad, 2010), its understanding and the identification
of those families for whom AD is associated with evident
emotional effects are considered essential for promoting
appropriate care. For this reason, the Childhood Atopic
Dermatitis Impact Scale (CADIS; Chamlin et al., 2005) was
created, specifically developed from directed focus sessions
with expert clinicians and parents of young children with
AD (Chamlin et al., 2004), based on the existing knowledge
about pediatric AD and QoL and on the following assumptions:
(1) IDQOL, CDLQI, and DFI, even if very brief and easy to
use, mainly assess physical symptoms and functioning,
while emotional effects are assessed only through a
few items;
(2) IDQOL, CDLQI, and DFI were developed by the same
group of physicians and are similar in format and design;
for this reason, the combined use of these questionnaires
may limit the diversity and the variety of characteristics
that are used when assessing QoL in patients with
AD (Rehal and Armstrong, 2011);
(3) there is not a unique instrument capable of assessing
both the child’s and the family’s QoL, at the same time,
in relation to the impact of AD.
The CADIS measures the multidimensional effects of AD
on QoL in both parents and their children, aged from birth to
6 years, showing good psychometrical properties (Chamlin
et al., 2005) and provides a patient-centered measurement
of AD severity that should prove useful in clinical research
(Chamlin et al., 2007). However, two aspects could be
addressed to improve the characteristics of this recent and
promising tool: the performance of this instrument in cultures
other than the United States, and the possibility of reducing
the length of the questionnaire to make it easier to use in
clinical settings.
This study analyzed the structure of the CADIS and its
validity and reliability in a sample of Italian parents of children
with AD aged birth to 6 years, with a twofold purpose:
(1) to assess whether it is actually applicable to a reality that
is culturally different from the United States;
(2) to assess whether it is possible to reduce the number of
items while maintaining appropriate psychometric
characteristics.
RESULTS
Sample characteristics
In all, 135 parents of children with AD participated in the
study. Children were aged 2–72 months (53% female)
and were diagnosed with mild, moderate, or severe AD
based on the SCORAD index (European Task Force on
Atopic Dermatitis, 1993). Parents were aged 23–48 years
(80% female). Detailed sample characteristics are presented
in Table 1.
Table 1. Characteristics of children and caregivers
(N=135)
Frequency, N (%)1
Children
Gender
Female 71 (53)
Male 62 (46)
Mean age 33 (SD=23; range 2–72 months)
Other diseases 18 (13)
Allergies 6 (4)
Asthma 6 (4)
Angioma 3 (2)
Other 3 (2)
Siblings 65 (48)
Sibling’s disease 21 (16)
Asthma 1 (1)
Dermatitis 14 (10)
Dermatitis and asthma 2 (2)
Other 4 (3)
School
Nursery 21 (16)
Kindergarten 38 (28)
Primary school 16 (12)
No 58 (43)
Mean age at AD diagnosis 14 (SD=23; range 2–72 months)
Mild AD (total SCORAD o25) 55 (41)
Moderate AD (total SCORAD 25–50) 52 (39)
Severe AD (total SCORAD 450) 20 (15)
Caregivers
Gender
Female 108 (80)
Male 25 (19)
Mean age 36 (SD=5; range 23–48 years)
Marital status
Single 19 (14)
Married 107 (80)
Separated 6 (4)
Occupation
Student 2 (2)
Housewife 19 (4)
Table 1 continued on the following page
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Of all participants, 66 parents (49%) completed the CADIS
again, after 2 days, and returned it by mail. Although this
response rate is below the mean of mail surveys published in
medical journals (which is approximately 60%; Asch et al.,
1997), socio-demographic characteristics of responders
did not significantly differ from those of non-responders.
Therefore, the extent of the non-respondent bias could be
considered limited.
Factor structure of CADIS
The 45 items of the CADIS were treated as elements of two
different scales based on the procedure followed by Chamlin
et al. (2005): a 16-item scale related to the impact of AD on
the child’s QoL, and a 29-item scale measuring the impact of
the child’s AD on the QoL of the family.
Kaiser–Meyer–Olkin and Bartlett’s test of sphericity for
both child- and parent-related items indicated that the data
set characteristics were adequate for performing factor
analysis.
Child-related items. For child-related items, the two
extracted factors accounted for 43.9% of the total variance.
All seven items originally belonging to the Child Symptoms
scale loaded on the first factor, with item 10 cross-loading on
both factors. It was attributed to the second factor, based
on higher factor loading.
Of the nine items originally belonging to the Child Activity
Limitations and Behavior scale, four items (items 2, 21, 29,
and 41) loaded on the second factor, two (items 27 and 34)
loaded on the first factor, one (item 22) loaded on
both factors, while items 24 and 43 did not reach an
acceptable loading on any factor, hence they were
eliminated. The cross-loading item was included in the
second factor, based on higher loading value.
The content of the eight items that formed the first factor
reflected the child’s AD symptoms, whereas the six items of
the second factor described the child’s activity limitations
and behavior, almost replicating the original item dimen-
sionality. Factor loadings of the retained items ranged from
0.33 to 0.88 for Child Symptoms, and from 0.40 to 0.81 for
Child Activity Limitations and Behavior.
A subsequent examination of the rotated factor matrix
led to the elimination of one item of the Child Symptoms
scale (item 27) and one item of the Child Activity Limitations
and Behavior scale (item 10), based on inadequate factor
loadings. Child-related scales are shown in Table 2.
Parent-related items. The total percentage of variance
explained by the three extracted factors was 43.7%.
Of the 17 items originally belonging to the Parent Emotions
scale, 15 loaded exclusively on the first factor, one (item 18)
loaded on the second factor, and one (item 16) did not
reach an acceptable loading on any factor, hence it was
eliminated.
Of the nine items originally belonging to the Family and
Social Function scale, six loaded on the second factor,
one (item 30) loaded on the third factor, and one (item 11)
cross-loaded on two factors and was included in the third
factor, based on higher loading value. Item 20 did not reach
an acceptable loading on any of the three factors, hence it
was eliminated.
All the three items belonging to the Sleep scale loaded on
the third factor, with the addition of items 11 and 30.
Items in the first and second factors described the
parents’ emotions, and family functioning, respectively, as
in the original CADIS, while items in the third factor did
not only describe sleep-related issues, as in the original
CADIS, but rather obstacles to marital intimacy due to
the child’s AD.
A subsequent examination of the pattern matrix led to the
elimination of three items (items 19, 42, and 44) of the Parent
Emotions scale, one item (item 18) of the Family and Social
Function scale, and two items (items 11 and 30) of the last
factor, based on loadings below the selected cutoff value.
Parent-related scales are shown in Table 3.
Internal consistency reliability
CADIS subscales showed acceptable internal consistency
estimates (0.77–0.90) with Cronbach’s a coefficients and
corrected item–total correlations in the 0.32 to 0.81 range.
a-Value for the total CADIS was 0.95. This high a-value may
be indicative of item redundancy.
The reduced version of the CADIS also showed good
reliability, with a coefficients between 0.72 and 0.89 and
corrected item–total correlations in the 0.33 to 0.83 range.
a-Value for the total 33-item CADIS was 0.90. The lower
a-value of the total 33-item scale, compared to that of the
longer CADIS, may be indicative of a reduction in item
redundancy. Cronbach’s a-values for child and parent-related
items are displayed in Tables 2 and 3.
Table 1. Continued
Frequency, N (%)1
Unemployed 7 (5)
Employed 105 (78)
Mean absence from work 0.6 (SD=2; range 0–15 days)
Diseases 56 (41)
AD 13 (10)
Allergies 18 (13)
Asthma 3 (2)
Dermatitis 5 (4)
Other 17 (13)
Economic costs
Low 28 (21)
Adequate 45 (33)
High 60 (44)
Abbreviations: AD, atopic dermatitis; SCORAD, Severity Scoring of
Atopic Dermatitis.
1Percentages do not always add up to 100 because of missing values.
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Test–retest reliability
Temporal stability was explored in a subsample of 66 parents
who were asked to complete the CADIS again after 48 hours.
Spearman’s r coefficients indicated acceptable test–retest
reliability with correlations of 0.92 for the 41-item
CADIS, 0.90 and 0.80 for Child Symptoms and Child Activity
Limitations and Behavior, respectively (for all r values,
Pp0.001). For the three parent-related scales, test–retest
reliability estimates were 0.73 (Family and Social Function)
and 0.87 (Parent Emotions and Parent Sleep) (for all r values,
Pp0.001).
The 33-item CADIS showed test–retest coefficients of
0.91 (total scale), 0.91 (Child Symptoms), and 0.78 (Activity
Limitations and Behavior) for the child-related scales, and
0.85 (Parent Emotions), 0.67 (Family and Social Function),
and 0.87 (Parent Sleep) for the parent-related scales,
respectively (for all r values Pp0.001).
Concurrent validity
Concurrent validity evaluation demonstrated both the
41- and 33-item CADIS to be significantly correlated with
SCORAD, IDQOL-CDLQI, and DFI scores.
Spearman’s correlations with the SCORAD ranged
between 0.27 and 0.58 for the long CADIS and between
0.24 and 0.57 for the 33-item CADIS, with lower correlations
with the objective SCORAD and higher correlations with the
subjective SCORAD.
For the long CADIS, correlation coefficients ranged
between 0.40 and 0.75 with the IDQOL, between 0.38
and 0.62 with the CDLQI, and between 0.51 and 0.68 with
the DFI.
For the 33-item CADIS, correlations ranged between 0.32
and 0.74 with the IDQOL, 0.37 and 0.63 for the CDLQI,
and 0.46 and 0.66 with the DFI. Correlation coefficients
for both CADIS versions are presented in Table 4.
In summary, a greater impact of AD on the QoL of
children and their families (measured with CADIS) was
associated with a more severe AD (measured with the
SCORAD Index), a lower dermatological QoL in children
and infants (measured with IDQOL or CDLQI), and a higher
impairment of family life (measured with the DFI).
Discriminant validity
According to the total SCORAD scores at baseline, children
were classified into three groups depending on their AD
severity: mild (n¼55; 41%), moderate (n¼ 52; 39%), and
severe (n¼ 20; 15%). Kruskal–Wallis test for difference
between AD severity groups was significant for all CADIS
domains (H(2): 12.32–25.65 for the long CADIS; H(2): 10.5–26
for 33-item CADIS; Pp0.01). Subsequent post-hoc pairwise
comparisons, using the Mann–Whitney test with Sˆida´k
correction (Po0.017) (Table 5), showed a significant
difference between the three severity groups on all five
CADIS domains, with four exceptions: the pairwise compar-
isons between patients with moderate and severe AD did not
reach statistical significance in the Child Activity Limitations
and Behavior and in the Parent Emotions domains, whereas
the Family and Social Function and Parent Sleep domains did
not discriminate between the mild and moderate AD groups
for both the 41- and the 33-item CADIS.
DISCUSSION
One of the aims of this study was to offer a contribution to
the validity and reliability of the CADIS (Chamlin et al.,
2005), evaluating whether it performs well when applied to a
different population.
Overall, our results indicate acceptable validity and
reliability of the CADIS in an Italian sample and almost
support the original factor structure of the CADIS, with
Table 2. Exploratory factor analysis for child-related
items
Factors and loadings
Items
Child
Symptoms
Child Activity
Limitations
and Behavior
9. My child scratches or rubs his/her skin. 0.88 0.19
17. My child seems to be restless or hyperactive
because of this skin condition.
0.82 0.05
14. My child’s skin seems to be painful or
irritated.
0.82 0.22
6. This skin condition makes my child fussy or
irritable.
0.82 0.07
1. This skin condition affects how well my child
sleeps.
0.71 0.03
12. My child seems to cry more because of this
skin condition.
0.63 0.23
34. My child misbehaves more because of this
skin condition.
0.52 0.06
27. Certain fabrics or clothes seem to bother my
child’s skin.1
0.33 0.10
2. Because of this skin condition, I limit my
child’s outdoor activities such as playing at
parks or beaches.
0.18 0.82
29. It is difficult to discipline my child because
of this skin condition.
0.11 0.59
21. Taking a bath makes my child
uncomfortable.
0.11 0.54
41. Children seem to avoid touching or playing
with my child because of this skin condition.
0.06 0.54
22. My child’s itching or scratching affects his/
her play.
0.33 0.52
10. This skin condition makes my child
feel frustrated.1
0.36 0.40
43. My child dislikes having creams or ointments
applied to his or her skin.
0.28 0.30
24. My child scratches his/her skin to
get attention
0.10 0.23
Cronbach’s alpha 0.88 0.79
Cronbach’s alpha—short version 0.89 0.74
Note: Extraction method: principal axis factoring with Promax rotation.
Items in bold indicate the item’s primary factor.
1Item excluded from the short version.
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41 items distributed among five domains. The elimination of
four items from the original version was probably due to
the different factor extraction method adopted in this study
(i.e. principal axis factoring vs. principal component
analyses).
However, we also found some differences on the
composition of domains. Specifically, the Parent Sleep scale
corresponded to the original scale, but it included two
additional items describing general obstacles to marital
intimacy.
The loading of some items on different subscales may be
due to cultural differences between Italian and US parents of
children with AD, in how the disease affects child and family
functioning, or in the way they interpret the content of the
CADIS. In relation to item 27 (bothered by fabrics or clothes)
and 34 (misbehaves more), Italian parents seemed to put
greater emphasis on how the child experienced the disease,
rather than referring to an obstacle in doing different
activities. This difference could reflect previous results from
Chamlin et al. (2004), where US parents seemed to complain
Table 3. Exploratory factor analysis for parent-related items
Factors and loadings
Items
Parent
Emotions
Family and
Social Function
Parent
Sleep
13. I worry that my child’s skin condition will continue. 0.73 0.20 0.02
39. My child’s skin condition makes me feel sad or depressed. 0.72 0.01 0.09
38. I worry that this skin condition will affect my child’s self-esteem. 0.71 0.12 0.22
28. I worry that my child is exposed to things that may worsen this skin condition. 0.70 0.19 0.04
23. I feel helpless about my child’s skin condition. 0.68 0.25 0.27
15. I am frustrated with my child’s skin condition. 0.68 0.03 0.09
33. I worry that this skin condition will affect my child’s ability to make friends. 0.67 0.25 0.30
25. I am bothered by the reaction of strangers to this skin condition. 0.67 0.08 0.04
32. I worry about the side effects from treatments for this skin condition. 0.62 0.16 0.26
37. I am angry that my child has this skin condition. 0.60 0.03 0.05
35. This skin condition has affected how confident I feel about my child’s medical care. 0.60 0.19 0.14
26. I am disappointed that my child has this skin condition. 0.60 0.01 0.09
42. I blame myself or feel guilty that my child has this skin condition.1 0.39 0.29 0.06
19. I worry about the costs of my child’s skin condition1 0.37 0.23 0.13
44. I am embarrassed by the way my child’s skin looks.1 0.33 0.28 0.09
20. My child’s skin condition affects my spouse’s or my work performance due to missed time
and decreased productivity.
0.30 0.29 0.28
45. My child’s skin condition makes it hard to do what I enjoy. 0.04 0.81 0.05
4. I am bothered that this skin condition affects our vacation plans. 0.32 0.80 0.09
7. I am bothered that my family stays home more because of this skin condition. 0.13 0.64 0.15
40. My child’s skin condition has affected my decision to have other children. 0.11 0.60 0.12
5. This skin condition affects our social life. 0.01 0.58 0.20
8. I am bothered that this skin condition affects our relationships with relatives. 0.01 0.53 0.22
18. I am bothered by how much time is needed to care for my child’s skin condition.1 0.27 0.43 0.12
16. I/we avoid taking photos of my child because of this skin condition. 0.19 0.29 0.04
31. My child sleeps in my bed because of this skin condition. 0.24 0.01 0.90
3. My child’s skin condition affects how well my spouse and I sleep. 0.02 0.04 0.70
36. I am bothered by my child sleeping in my bed. 0.03 0.01 0.51
11. I worry about leaving my child with others (babysitters, relatives) because of this skin condition.1 0.33 0.08 0.43
30. My child’s skin condition has strained my relationship with spouse or partner.1 0.21 0.20 0.40
Cronbach’s alpha 0.90 0.82 0.77
Cronbach’s alpha—short version 0.89 0.81 0.72
Note: Extraction method: principal axis factoring with Promax rotation.
Items in bold indicate the item’s primary factor.
1Item excluded from the short version.
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more about the clothing restriction for their children caused
by AD, while the Italian study by Ricci et al. (2007) showed
how the children’s QoL was compromised by symptoms
(particularly pruritus) and mood worsening.
In relation to item 18 (bothered by need of time), Italian
parents seemed to consider the extra time needed to take care
of their child with AD as a limitation to the social dimensions
of their family’s life instead of as an emotional aspect related
to the child’s disease. Anyway, it is interesting to note that, in
the prototype version of the CADIS (Chamlin et al., 2005),
this item was included in the Parent Physical Functioning
domain and only subsequently was moved into the Parent
Emotions scale (Chamlin et al., 2007), so this aspect should
be further investigated.
Item 10 (feel frustrated) would show in Italian sample a
sense of frustration tied to the limitations in the child’s
activities, rather than a proper symptom. As for item 18,
social dimensions could emerge as relevant issues in Italian
context and should be further investigated.
Items 11 (worried about leaving the child with others) and
30 (strained relationship with partner) showed strong
correlations with the other three sleep items and seemed
to particularly relate to a negative influence of AD on the
parent’s sleep and relationship. In this case, the Italian
version seems to be more sensitive to how the child’s AD
might impact or interfere with the parent’s relationship and
intimacy. The presence of a higher number of items included
in the new Parent Sleep scale, compared to the original one,
may evidence a stronger discomfort perceived by the Italian
sample in this domain; the study by Ricci et al. (2007)
underlined how the child’s AD significantly affected the
family’s QoL, especially in relation to sleep and tiredness,
and this result was also evidenced in the Swedish study by
Ganemo et al. (2007), probably suggesting the presence of
cultural differences between European and US populations.
The 33-item CADIS reduced part of the differences
between the Italian and the US versions; however, the nature
of the few differences that still remain between the two
factorial structures of the CADIS should be further investi-
gated, always taking cultural influences into consideration.
Concurrent validity of the CADIS was indicated by
significant positive relationships with the SCORAD, and with
IDQOL, CDLQI, and DFI scores. As expected, correlations
were mostly adequate to be reasonable with the SCORAD,
and good to excellent with IDQOL, CDLQI, and DFI. As
expected, correlations with the subjective SCORAD were
higher than with the objective SCORAD, because
the subjective SCORAD includes evaluations on sleep
and pruritus, investigated by the CADIS as well, while the
objective SCORAD only includes measures on severity and
extent of AD.
Furthermore, a good correlation was found between the
SCORAD and the CADIS Child Symptoms subscale, in
agreement with findings from the original CADIS (Chamlin
et al., 2007). This result can be explained by the fact that the
Child Symptoms subscale measures the presence of symp-
toms in the child (i.e. scratching, restlessness, fussiness, sleep
loss), which are clinically correlated with increasing disease
Table 4. CADIS concurrent validity estimates with Spearman’s q correlation coefficient
Objective SCORAD Subjective SCORAD Total SCORAD IDQOL1 CDLQI2 DFI3
41-Item CADIS domain
Child Symptoms 0.37 0.58 0.44 0.75 0.60 0.62
Child Activity Limitations 0.31 0.44 0.36 0.62 0.54 0.51
Parent Emotions 0.30 0.51 0.36 0.62 0.38 0.58
Family and Social Function 0.27 0.31 0.32 0.40 0.62 0.55
Parent Sleep 0.31 0.40 0.36 0.62 0.53 0.61
Total 41-item CADIS 0.38 0.57 0.44 0.74 0.58 0.68
33-Item CADIS domain
Child Symptoms 0.39 0.57 0.45 0.74 0.61 0.61
Child Activity Limitations 0.30 0.38 0.34 0.59 0.53 0.46
Parent Emotions 0.30 0.52 0.35 0.63 0.37 0.58
Family and Social Function 0.24 0.24 0.28 0.32 0.63 0.49
Parent Sleep 0.30 0.35 0.35 0.55 0.52 0.53
Total 33-item CADIS 0.38 0.56 0.44 0.74 0.56 0.66
Abbreviations: CADIS, Childhood Atopic Dermatitis Impact Scale; CDLQI, Children’s Dermatology Life Quality Index; DFI, Dermatitis Family Impact
10-item questionnaire; IDQOL, Infants Dermatitis Quality of Life Index; SCORAD, Severity Scoring of Atopic Dermatitis.
All correlations are significant for Pp0.01 (two-tailed).
1N=102 (children aged 0–4 years).
2N=33 (children aged 44 years).
3N=126 (children aged 46 months).
www.jidonline.org 2539
E Neri et al.
Italian Validation of the Childhood Atopic Dermatitis Impact Scale
severity in most cases of AD. Overall, the moderate
correlations found between the CADIS and the SCORAD
scores indicate that, compared to the SCORAD, the CADIS
may measure disease-related aspects that are closely asso-
ciated with individual child and family experiences and that
are not only based on disease severity and clinical findings
alone. The mainly excellent correlations between the
CADIS domains and IDQOL, CDLQI, and DFI, which
were not considered in the original study by Chamlin et al.
(2007), indicate that the Italian CADIS has good concurrent
validity.
Comparisons of the CADIS subscales and overall scores
among AD severity groups revealed that not all domains of
the Italian CADIS were able to differentiate each severity
group. Family and Social Function and Parent Sleep domains
did not differentiate between patients with mild and
moderate AD, whereas Activity Limitations and Behavior
and Parent Emotions could not detect significant differences
between moderate and severe AD groups.
Differently from the original version, the Italian CADIS
does not sufficiently distinguish between adjacent AD
severity groups and seems to better discriminate between
extreme groups of patients (mild vs. severe). Considering that
the original validation by Chamlin et al. (2007) was carried
out on 270 subjects, our result could be partly explained
taking into account a lower number of individuals; however,
they would need further investigations.
Regarding reliability, according to the standards recom-
mended by Streiner and Norman (2008), the Italian CADIS
domains demonstrated a high degree of internal consistency,
with Cronbach’s a-values ranging from 0.77 to 0.90 and
corrected item–total correlations above the recommended
level of 0.30. Cronbach’s a-values for the total CADIS and for
all domains were comparable to those found for the original
questionnaire, except Family and Social Function, for which
the smaller internal consistency was probably due to the
reduction in scale length. However, some item redundancy
was indicated by a total scale a of 0.95.
The internal consistency coefficients reported in our study
suggest that each CADIS domain addresses a somewhat
different aspect of AD impact, thus supporting the multi-
dimensionality of the construct measured and the existence
of specific QoL domains that parents perceive as being
affected by AD.
Regarding temporal stability, the second administration of
the Italian CADIS revealed a good to excellent test–retest
reliability, with Spearman’s correlation coefficients ranging
between 0.73 (Family and Social Function) and 0.92 (overall
CADIS). Nevertheless, the good temporal stability may be
due to the short test–retest interval, selected to minimize the
probability of treatment-induced changes in AD severity, in
accordance with the original study (Chamlin et al., 2007).
Owing to the short interval between test and retest, we
cannot exclude a recall bias in the caregivers’ answers.
The second aim of this study was to address the possibility
of reducing the number of items of the CADIS, to facilitate its
use in clinical practice. In fact, although long forms of
questionnaires are useful for research, short forms may have a
wider applicability in clinical settings, where it is important
to minimize the burden for the respondent. The overall
41-item CADIS reliability exceeded the recommended
value of 0.90 (Streiner and Norman, 2008), indicating
some item redundancy or content overlap. This encouraged
a reassessment of the correlation matrix and a reduction in
the number of items, using more restrictive selection
criteria.
The shorter 33-item CADIS thus obtained showed good
psychometric characteristics. Regarding concurrent validity,
the 33-item CADIS almost replicated the pattern of correla-
tions found for the 41-item version, with the exception of
lower, but still adequate, correlations between Family and
Social Function and IDQOL. Regarding discriminant validity,
the 33-item better discriminated between extreme groups of
patients, just as the long CADIS. Regarding reliability,
corrected item–total correlations were all above the recom-
mended level of 0.30. The fact that the a-values of the five
factors only slightly changed in the short version indicates
that the elimination of 12 items makes the CADIS easier to
complete without lowering its internal consistency. Further-
more, the internal consistency estimate for the overall scale
entered the range recommended by Streiner and Norman
(2008), indicating a reduction in item redundancy.
One of the study limitations was the moderate sample size
that did not allow the use of all the 45 CADIS items in a single
factor analysis, as would have been statistically ideal.
Recommendations by Mundfrom and co-workers (2005) for
the minimum necessary sample size were satisfied in this
study. However, other authors recommend 5:1 as a minimum
subject/item ratio (Hair et al., 2006), and, in the case of
29 parent-related items and 135 subjects, this standard would
have been missed by a rather small amount (4.7:1), while it
would have been definitely broken in the case of 45 item and
135 subjects. A further validation with a much larger sample
size would allow the use of Item Response Theory models,
useful to better understand the Italian CADIS dimensionality
and examine the probability of endorsing each response
option within each CADIS item as a function of AD severity.
Besides, future studies should investigate the CADIS test–
retest reliability over a longer period of time and, in order to
exclude possible changes in AD severity during the test–retest
period, the second CADIS administration should follow a
new SCORAD assessment.
In conclusion, the CADIS is a reliable and valid instrument
when applied to the Italian population of parents of children
with AD. Of note, the Italian version has psychometric
properties that are generally similar to those of the original
version, although some items had to be relocated into
different factors, and discriminant validity requires further
investigations. The reduced 33-item version of the CADIS
proposed in this study has been shown to maintain good
psychometric characteristics, and, therefore, we recommend
the use of this shortened version in future research.
Our findings provide further evidence that the CADIS
is a reliable and a valid five-dimensional self-administered
instrument for measuring the impact of AD on QoL in
affected young children and their parents.
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MATERIALS AND METHODS
Sample population
The study included consecutive families with a child with AD (o6
years of age), seen for a dermatological visit at the Bufalini Hospital
in Cesena, Italy, in the period May 2007–September 2010. A
dermatologist assessed the presence of AD according to the criteria
of Hanifin and Rajka (1980) and completed the SCORAD index for
each patient to classify children on the basis of the AD severity. After
the visit, a psychologist explained the research project and gave
the study instruments to the subjects.
All parents also received a copy of the same questionnaires to
complete again after 2 days, and were instructed to mail it back to
the investigators. Stamped return envelopes and other strategies
were used to encourage the response to the postal questionnaire
(Edwards et al., 2002).
All participants provided written informed consent before
entering the study. The study was performed with ethical approval
by the Bufalini Hospital and Department of Psychology, in
adherence to the Declaration of Helsinki Principles.
Instruments
The measures used in the study were as follows:
CADIS: The CADIS (Chamlin et al., 2005) consists of 45 items
divided into five domains: Child symptoms (7 items), Child activity
limitation and behavior (9 items), Parent emotions (17 items), Family
and social function (9 items), and Parent sleep (3 items). Each item
is scored from 0 (‘‘never’’) to 4 (‘‘all the time’’) and refers to the
parent’s perceptions in the last 4 weeks. A total CADIS score is
obtained by adding all the domain scores together. The original
version of the CADIS was translated into Italian following the
international guidelines suggested by Guillemin et al. (1993) and by
the MAPI Research Institute (Acquardo et al., 1996).
SCORAD: The SCORAD index (European Task Force on Atopic
Dermatitis, 1993) is a well-validated instrument measuring the
severity of AD. The SCORAD index assesses disease extent and
evaluates five clinical characteristics to determine disease severity:
erythema, edema/papulation, oozing/crusts, excoriation, and liche-
nification. SCORAD also evaluates subjective symptoms of pruritus
and sleep loss with Visual Analogue Scales. These three aspects
combined (extent of disease, disease severity, and subjective
symptoms) give a maximum possible score of 103 and AD severity
can be globally classified as mild (score o25), moderate (25–50), or
severe (450).
IDQOL: The IDQOL (Lewis-Jones et al., 2001) is a 10-item
disease-specific measure for children with AD between 0 and 4
years old and completed by the caregiver. The items assess the
infant’s difficulties tied to eczema, that is, itching and scratching,
difficulties with sleeping, playing, family activities, eczema treat-
ment, dressing, and bathing. The questions are graded from 0 to 3.
A total score is calculated (range 0–30). In this study, Cronbach’s a
for the IDQOL was 0.89.
CDLQI: The CDLQI (Lewis-Jones and Finlay, 1995) is a 10-item
skin-specific measure for children between 4 and 16 years old,
assessing physical symptoms (i.e. itching), as well as psychosocial
issues (i.e. bullying, school performance, sports participation) Each
item response is scored from 0 (‘‘not at all’’) to 3 (‘‘very much’’).
The total score is between 0 and 30. In this study, Cronbach’s a for
the CDLQI was 0.87.
Table 5. Mann–Whitney U-test for differences between AD severity group scores
Pairwise comparisons between AD severity groups1
Mild versus moderate AD Mild versus severe AD Moderate versus severe
Mean rank Mean rank U Mean rank Mean rank U Mean rank Mean rank U
41-Item CADIS domain
Child Symptoms 45.45 63.05 959.5* 31.19 56.73 175.5* 31.26 50.13 247.5*
Child Activity Limitations 46.94 61.47 1041.5* 33.28 50.98 290.5* 34.29 42.25 405.0
Parent Emotions 45.75 62.72 976.5* 32.67 52.65 257.0* 34.79 40.95 431.0
Family and Social Function 50.45 57.76 1234.5 32.35 53.55 239.0* 32.66 46.48 320.5*
Parent Sleep 50.35 57.86 1229.5 31.00 57.25 165.0* 30.19 52.90 192.0*
Total 41-item CADIS 45.51 62.98 963.5* 31.02 57.20 166.0* 32.23 47.60 298.0*
33-Item CADIS domain
Child Symptoms 45.44 63.06 959.0* 31.11 56.95 171.0* 31.26 50.13 247.5*
Child Activity Limitations 47.21 61.18 1056.5* 33.80 49.55 319.0* 34.54 41.60 418.0
Parent Emotions 45.81 62.66 979.5* 32.77 52.38 262.5* 34.82 40.88 432.5
Family and Social Function 51.19 56.97 1275.5 32.78 52.35 263.0* 32.80 46.13 327.5*
Parent Sleep 50.18 58.04 1220.0 31.65 55.48 200.5* 30.34 52.53 199.5*
Total 33-item CADIS 45.41 63.09 957.5* 31.20 56.70 176.0* 32.30 47.43 301.5*
Abbreviations: AD, atopic dermatitis; CADIS, Childhood Atopic Dermatitis Impact Scale; SCORAD, Severity Scoring of Atopic Dermatitis.
Mild AD group: N=55; moderate AD group: N=52; severe AD group: N=20.
1AD severity classification based on SCORAD total scores at baseline: mild (o25); moderate (25–50); severe (450).
*Po0.017 (significance level with Sidak’s correction for multiple comparisons).
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DFI: The DFI (Lawson et al., 1998) is a 10-item scale measuring
the impact of AD on families with an affected child, validated on a
sample of parents of AD children aged 6 months to 10 years old.
Items investigate the impact of AD on housework, food preparation
and feeding, sleeping, family leisure activity, shopping, expenditure,
fatigue, emotional distress, and relationships. Each item is scored
from 0 (‘‘not at all’’) to 3 (‘‘very much’’). In this study, Cronbach’s
a for the DFI was 0.90.
For all questionnaires, a higher score indicates a poorer QoL.
The IDQOL or the CDLQI was given to parents based on their
child’s age, and only parents of children 6 months or older completed
the DFI. Consequently, 102 caregivers completed the IDQOL and 33
the CDLQI, while 126 of them also completed the DFI.
Statistical analyses
Descriptive characteristics of variables. The distribution of
answers to individual CADIS items was checked before statistical
analyses. The data were considered within the limits of normal
distribution if skewness and kurtosis values did not exceed ±1.0
(Peat and Barton, 2005). For variables that were not normally
distributed, Spearman’s rank correlations were calculated.
Factor structure. Two separate exploratory factor analyses were
performed to determine how child- and parent-related items
clustered together, and to assess the factor structure of the CADIS
in the Italian sample. The factor extraction method used was
principal axis factoring, as it is appropriate in the case of significantly
non-normally distributed data (Fabrigar et al., 1999). It is also
appropriate for theoretical data exploration to arrive at a parsimo-
nious representation of the associations among measured variables.
Promax rotation was used because of its ability to provide
theoretically meaningful factors (Hair et al., 2006). Two and three-
factor solutions were forced for the 16 child- and the 29 parent-
related items, respectively, based on the original CADIS structure
(Chamlin et al., 2005).
The minimum necessary sample size was calculated
based on the recommendations by Mundfrom et al. (2005). The
number of variables to the number of factors ratio, assuming a low
communality level, was 8 for the child section and 9.6 for the parent
section. In both cases, a sample size of 130 was considered adequate.
Before performing principal axis factoring, the Kaiser–Meyer–-
Olkin measure of sampling adequacy and the Bartlett’s test of
sphericity were used to check whether the data set was suitable
for factor analysis. A Kaiser–Meyer–Olkin measure 40.70 and a
significant value for Bartlett’s test of sphericity indicated that the
variables were correlated highly enough to justify factor analysis
(Hair et al., 2006).
The minimum loading for an item to be retained was initially set
at 0.32, following Tabachnick and Fidell’s (2006) recommendations.
In this phase, the aim was to compare the factor structure of
the original US CADIS and of the Italian version; therefore, all the
original items were retained. In a second step, the factor matrix was
reviewed based on more strict criteria, to verify the possibility of
reducing the number of items, while maintaining acceptable
psychometric characteristics. A decision was made to drop items
with factor loadings below 0.50 (Hair et al., 2006).
All the subsequent analyses were performed on both the long
form of CADIS and the reduced CADIS obtained at the second step.
Internal consistency reliability. The internal consistency relia-
bility of each subscale that emerged from principal axis factoring
was verified with Cronbach’s a coefficient and corrected Spearman’s
item–total correlations. To ensure moderate correlations and avoid
item redundancy, lower and upper limits for Cronbach’s a were set
at 0.70 and 0.90, respectively (Streiner and Norman, 2008).
Corrected item–total correlation coefficients 40.30 (Streiner and
Norman, 2008) were considered an acceptable support for the
internal consistency.
Test–retest reliability. Temporal stability was assessed by calcu-
lating Spearman’s rank order correlations between test and retest for
each subscale and the total CADIS score. As in the original
validation study (Chamlin et al., 2007), the test–retest interval was
48 hours. Such a short time interval was chosen to guarantee the
stability of AD severity, as it typically changes within a few days
under treatment.
Concurrent validity. Concurrent validity was determined by
computing Spearman’s rank order correlations between each CADIS
domain score and objective, subjective and total SCORAD scores,
and total IDQOL, CDLQI, and DFI scores in case of skewed or
ordinal data (Antonisamy et al., 2010). We expected higher
correlations between CADIS and other instruments measuring the
effects of AD on both the child’s and parents’ QoL (IDQOL, CDLQI,
and DFI), and lower correlations with measures of disease severity
(objective and subjective SCORAD). Lindley (2001) suggests
evaluating concurrent validity coefficients as follows: o0.20 is
inadequate, 0.20–0.34 adequate, 0.35–0.44 reasonable, 0.45–0.54
good, and X0.55 is excellent.
Discriminant validity. Discriminant validity of CADIS was
assessed by comparing scores of three groups of patients based on
AD severity. The groups were formed on the basis of the total
SCORAD scores: mild (o25), moderate (25–50), and severe (450).
Differences among groups were tested using Kruskal–Wallis test.
Subsequent pairwise comparisons were performed using the
Mann–Whitney U-test adjusted by the ida´k correction for multiple
comparisons (Abdi, 2007).
Statistical significance was set at Po0.05. All analyses were run
with the SPSS.18 statistical software.
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